Upgrade to SI Premium - Free Trial

Protagonist Therapeutics (PTGX) PT Lowered to $13 at BMO Capital

March 26, 2018 10:22 AM
BMO Capital analyst M. Ian Somaiya lowered his price target on Protagonist Therapeutics (NASDAQ: PTGX) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles